Who is sponsoring NCT02952040?

NCT02952040 is sponsored by Astellas Pharma Inc.

What condition does NCT02952040 study?

NCT02952040 studies Healthy Subjects.

What drugs are being tested in NCT02952040?

Interventions: ASP1517, Lanthanum carbonate hydrate.

What is the status of NCT02952040?

NCT02952040 is currently COMPLETED.

Last reviewed 2017-01-23 · How we verify

Pharmacokinetic Study of ASP1517 - Evaluation of the Effect of Lanthanum Carbonate Hydrate on the Pharmacokinetics of ASP1517 in Non-elderly Healthy Adult Male Subjects -

NCT02952040 Phase 1 COMPLETED

The objective of this study is to evaluate the effect of lanthanum carbonate hydrate on the pharmacokinetics (PK) of ASP1517 in non-elderly healthy male subjects.

Details

Lead sponsor	Astellas Pharma Inc
Phase	Phase 1
Status	COMPLETED
Enrolment	18
Start date	2016-11
Completion	2016-12

Conditions

Healthy Subjects

Interventions

ASP1517
Lanthanum carbonate hydrate

Primary outcomes

Pharmacokinetics (PK) parameter of ASP1517 in plasma: AUCINF — Up to 72hr after each dosing
AUCinf: Area under the concentration-time curve from the time of dosing extrapolated to time infinity
PK parameter of ASP1517 in plasma: AUC24h — Up to 72hr after each dosing
AUC24h: Area under the concentration-time curve from the time of dosing to 24h
PK parameter of ASP1517 in plasma: Cmax — Up to 72hr after each dosing
Cmax: Maximum concentration

Countries

Japan